AWM
NMTR

AE Wealth Management’s 9 Meters Biopharma NMTR Stock Holding History

AE Wealth Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,359
Closed -$14K – 1937
2022
Q3 		$14K Buy
+3,359
New +$16.6K ﹤0.01% 1721

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

AE Wealth Management's NMTR Position: Q4 2022 in Review

AE Wealth Management sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 3,359 shares — an estimated $14K sold.

AE Wealth Management first reported a position in NMTR in Q3 2022 and held it in 1 quarter. The position peaked at $14K in Q3 2022. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • AE Wealth Management reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • AE Wealth Management sold 3,359 9 Meters Biopharma shares in Q4 2022, an estimated $14K.
  • AE Wealth Management first reported a position in 9 Meters Biopharma in Q3 2022 and held it in 1 quarter.
  • AE Wealth Management's 9 Meters Biopharma position peaked at $14K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on AE Wealth Management's 13F filing for Q4 2022, filed 31 Jan 2023.